Despite having similar disease characteristics and treatment patterns, elderly patients with HER2-positive advanced breast cancer aged ≥ 70 years experienced shorter chemotherapy durations than patients under the age of 70, as well as, poorer overall survival, and increased rates of adverse events in a real-world study.
The most interesting developments and approvals in breast cancer treatment in the last year and expectations regarding data that will be presented on at the upcoming 2020 San Antonio Breast Cancer Symposium.
Although the dual HER2 blockade combination is now considered a standard regimen for the treatment of patients with HER2-positive early-stage breast cancer, there are limited efficacy data regarding the use of the regimen in Asian populations.
In an interview with Targeted Oncology, William J. Gradishar, MD, discussed the current treatment options for patients with HER2-positive breast cancer, including the recently approved therapies from the FDA. He also shared his insights on treating patients with brain metastases, in particular.
Until recently, few options existed for patients with HER2-positive breast cancer who progressed on earlier lines of therapy. Recent approvals of 3 drug combinations offer new tools that may prolong life and control brain metastases across lines of therapy.
A number of targeted agents have been approved in the setting of metastatic breast cancer, which has allowed for more personalized treatment approaches and underscores the importance of genomic testing.
Although HER2 positivity has been identified as a predictive factor of response to chemotherapy, it remains controversial considering that responses to chemotherapy can vary in patients with certain disease characteristics.